tradmap

LIMN Earnings Liminatus Pharma, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$0 -$0 $0 2024 2025
EPS
Net income (annual)
-$10M -$5M $0 2024 2025
Net income
Return on equity (annual)
0% 52% 104% 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$2 -$1 $0 Q1 '24 Q2 '24 Q3 '24 Q1 '25 Q2 '25 Q3 '25 Q1 '26 Q2 '26
EPS
Net income (quarterly)
-$8M -$4M $113287 $0 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
Net income
Return on equity (quarterly)
-468% 190% 847% 0% Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26
ROE

Reported EPS history

1–10 of 10
Q2 20262026-06-30-0.062026-08-1410-Q
Q1 20262026-03-31-0.032026-05-1510-Q
FY 20252025-12-31-0.432026-03-3110-K
Q3 20252025-09-30-0.092025-11-1410-Q
Q2 20262025-06-30-0.012026-08-1410-Q
Q1 20262025-03-31-0.022026-05-1510-Q
FY 20252024-12-31-0.202026-03-3110-K
Q3 20252024-09-30-0.192025-11-1410-Q
Q2 20252024-06-30-0.162025-10-0610-Q
Q1 20252024-03-31-2.472025-06-0210-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.